Indirect targeting of MYC and direct targeting in combination with chemotherapies are more effective than direct mono-targeting in triple negative breast cancer
MYC amplification is disproportionally elevated in triple-negative breast cancer (TNBC) compared to other subtypes of breast cancer. Indeed, MYC has long been considered an undruggable oncogene using conventional drug design strategies or small molecules. We hypothesized that targeting MYC using asy...
Saved in:
| Main Authors: | Negesse Mekonnen, Hobin Yang, Nirmal Rajasekaran, Kyoung Song, Yoon-La Choi, Young Kee Shin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523324003309 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology
by: Yingying Duan, et al.
Published: (2025-07-01) -
MYC and the unfolded protein response in cancer: synthetic lethal partners in crime?
by: Tingting Zhang, et al.
Published: (2020-04-01) -
PAK4 phosphorylates and stabilizes MYC to promote acute myeloid leukemia
by: Ting Xie, et al.
Published: (2025-10-01) -
A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting
by: Fenglin Li, et al.
Published: (2025-04-01) -
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma
by: Arianna Giacomini, et al.
Published: (2024-11-01)